Repetitive transcranial magnetic stimulation in children and adolescents with autism spectrum disorder: study protocol for a double-blind, sham-controlled, randomized clinical trial.

Publication date: Jul 07, 2025

The prevalence of autism spectrum disorder (ASD) has significantly increased over recent decades, representing a serious public health issue. Neurobiological characteristics of ASD include imbalances in cortical excitation and inhibition, along with disruptions in neural network connectivity. Repetitive transcranial magnetic stimulation (rTMS) may provide a therapeutic option when cognitive-behavioral therapy alone is insufficient to alleviate core symptoms. This article outlines the protocol for a double-blind, sham-controlled, randomized study assessing low-frequency rTMS targeting the bilateral dorsolateral prefrontal cortex (DLPFC) in children and adolescents with ASD. The objective is to evaluate the efficacy of rTMS compared to sham stimulation. Forty patients with ASD, aged 7-18 years and with different levels of clinical severity, will be randomized into an active treatment group (n = 20) and a sham control group (n = 20). Each participant will receive 18 low-frequency (2 Hz) rTMS sessions over 9 weeks, administered at 90% of the motor threshold with 180 pulses per session. Treatment will target the left DLPFC (six sessions), the right DLPFC (six sessions), and both hemispheres (six sessions). Clinical, cognitive, and neurophysiological assessments will be conducted at baseline, post-treatment, and 1-month follow-up. Biological samples (blood, urine) will be collected at each time point to evaluate changes in various biomarkers, including tryptophan metabolites, neurotrophic factors, neurotransmitters, and inflammatory mediators. Safety will be monitored through semi-structured interviews and adverse event reporting. This study aims to identify a safe rTMS protocol for ASD that could complement existing therapies. By assessing the cognitive domains and the clinical and biochemical profiles most responsive to rTMS, this study may contribute to optimize ASD treatments and enhance therapeutic outcomes in pediatric populations. The study protocol is registered at “ClinicalTrials. gov” with the following ID: NCT06069323.

Open Access PDF

Concepts Keywords
Autism Adolescent
Blood Adolescent Behavior
Clinicaltrials Age Factors
Decades Autism Spectrum Disorder
Nct06069323 Autism spectrum disorder
Biomarkers
Child
Child Behavior
Cognition
Dorsolateral Prefrontal Cortex
Dorsolateral prefrontal cortex
Double-Blind Method
Female
Humans
Male
Neurostimulation
Randomized controlled trial
Time Factors
Transcranial Magnetic Stimulation
Treatment Outcome

Semantics

Type Source Name
disease MESH autism spectrum disorder
disease MESH tryptophan
drug DRUGBANK L-Tryptophan
pathway REACTOME Reproduction
disease MESH mental disorder
drug DRUGBANK Isoxaflutole
disease MESH pathogenesis
disease MESH anomalies
disease MESH cortical dysplasia
disease MESH neurodevelopmental disorders
disease MESH inflammation
disease MESH oxidative stress
disease MESH neuroinflammation
disease MESH autism
pathway REACTOME Metabolism
drug DRUGBANK Quinolinic Acid
drug DRUGBANK Kynurenic Acid
drug DRUGBANK Ketamine
pathway REACTOME Release
disease MESH seizure
disease MESH dyspraxia
disease MESH tic
drug DRUGBANK Tilmicosin
drug DRUGBANK L-Valine
drug DRUGBANK Methionine
drug DRUGBANK gamma-Aminobutyric acid
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Dopamine
drug DRUGBANK Serotonin
drug DRUGBANK Ranitidine
drug DRUGBANK Etoperidone
drug DRUGBANK Trestolone
drug DRUGBANK Ethionamide
drug DRUGBANK Adenosine
disease MESH febrile seizures
disease MESH brain tumors
disease MESH syndrome
disease MESH tuberous sclerosis
disease MESH psychosis
disease MESH infection
drug DRUGBANK Dimercaprol
drug DRUGBANK Ibuprofen
disease MESH attention deficit hyperactivity disorder
drug DRUGBANK Abacavir
disease MESH Depression
disease MESH Anxiety
drug DRUGBANK Tretamine
pathway REACTOME Digestion
drug DRUGBANK Ademetionine
drug DRUGBANK Coenzyme M
disease MESH RFLP
drug DRUGBANK Esomeprazole
pathway KEGG Purine metabolism
drug DRUGBANK Licofelone
disease MESH sleep disorder
pathway REACTOME Pervasive developmental disorders
disease MESH learning disorder
drug DRUGBANK Albendazole
disease MESH schizophrenia

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *